Testing malaria medicines in uncomplicated falciparum malaria
Part of Infections clinical trials.
This trial studies how well and how safely different anti-malaria medicines work for people who have uncomplicated malaria caused by Plasmodium falciparum. You may be eligible if you have a confirmed infection with a certain parasite level and do not have signs of severe disease or major health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age must match the study group: 18+ for one part, 12–17 for another, and 2–11 for another
- You must have confirmed “uncomplicated” falciparum malaria only (no other malaria type) with a specific parasite level in your blood
- You must meet weight limits that vary by study part (adults typically about 35–90 kg; children part needs at least 10 kg)
- You must have fever now or within the last 24 hours (temperature thresholds are specified)
- You must not have severe/complicated malaria, mixed malaria infections, or clinically significant anemia/low hemoglobin
- You must not be pregnant or breastfeeding, and must be able/willing to use effective birth control if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new malaria treatment for children with mild (uncomplicated) malaria. The goal is to see if the treatment safely and effectively clears the infection.
This study compares a combination of three medicines to treat uncomplicated malaria, to see if it works as well and is as well tolerated as a two-medicine combination. You may join if you have a specific type of malaria infection in a mild form and meet safety requirements.
This study tests how well malaria treatments work in Ethiopia. It aims to find the best medicines for uncomplicated malaria caused by certain parasites, helping patients recover fully and preventing future drug resistance.
This study tests a new investigational drug (GSK4425689A) for the first time in humans. It is a healthy volunteer study to check the safety, side effects, and how the drug moves through the body. It may help in the future development of treatments for malaria.
This study tests a new malaria pill in adults with uncomplicated malaria (mild form). The pill aims to treat the infection, and participation involves monitoring and follow-up visits.
This trial tests whether adding a cancer drug called imatinib to standard malaria treatment works better and is safe. Researchers will enroll adults and children with uncomplicated malaria caused by P. falciparum parasites and monitor them in the hospital for 2–3 days.
Hear when a new Uncomplicated Plasmodium Falciparum Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.